Does Gemtesa have a patient assistance program?

Cognitive decline, which may include dementia, memory loss and confusion, is not a known side effect for Gemtesa (vibegron) or the beta-3 agonist class as a whole. In addition, a study found the use of anticholinergic medications among patients with overactive bladder (OAB) was associated with an increased risk of new-onset dementia compared to beta-3 agonist users. Continue reading

Gemtesa (vibegron) starts working almost immediately – within a few days of first taking it, with noticeable improvements in urinary urgency, frequency, and incontinence noted in clinical trials at 2 weeks which were reported as significant by 12 weeks.

After 12 weeks, people taking Gemtesa had 2 fewer daily leakage episodes compared to 1 fewer episode in those taking placebo, 2 fewer bathroom visits (versus 1 fewer with placebo), and 3 fewer “urge to go” visits a day compared to 2 fewer with placebo. Continue reading

No, it isn’t common for Gemtesa (vibegron) to cause high blood pressure. In the phase 3 EMPOWUR trial of patients taking 75 mg of Gemtesa per day, Gemtesa had low rates of high blood pressure (1.7%) that were similar to placebo. Continue reading